EGFR and neoplasm: In 2009, Yung et al reported the feasibility of using digital arrays in the detection of EGFR mutations in tumor tissues from patients with advanced metastatic NSCLC at a detection limit of 0.1% of the total number of 10,000 EGFR sequences (13).